Roxadustat CKD Doubts Fanned By FibroGen Data Blunder
Focus Moves To 15 July Cardio-Renal FDA Adcomm
AstraZeneca's partner FibroGen stunned investors and regulators by announcing that previously disclosed cardiovascular safety data for CKD candidate roxadustat included changes made post hoc, rather than as pre-specified with the US FDA.
